Study With a Topical Gel to Treat Common Warts in Adults

Graceway Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Warts

Treatments: Drug: Resiquimod

Study type: Interventional

Funder types: Industry

Identifiers

NCT00117923

1514-RESI

Details and patient eligibility

About

The primary purpose of this study is to evaluate the effectiveness in adults of four different strengths of resiquimod gel applied to common wart(s) five times a week for four weeks.

A second purpose is to evaluate the safety of the drug.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of common warts
• Two forms of birth control

Exclusion criteria

• Pregnant or breast feeding
• Other types of warts, ie. plantar
• Currently participating in another clinical study
• Chronic viral hepatitis B or C

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: Single Blind